Table 1.
Selected trials of chemoradiation for LS-SCLC comparing 45 Gy/30 fractions BID regimen with QD TRT regimens.
| Study | Completed | N | TRT in comparison group | Chemotherapy (cycles) | 2-year OS (%) | Median OS (months) | p-value | Grade 3–4 esophagitis (%) | p-value |
|---|---|---|---|---|---|---|---|---|---|
| INT-0096 (29) | Yes | 471 | 45 Gy/25 fractions QD | EP (4) | 47 (BID) vs. 41 (QD) | 23 (BID) vs. 19 (QD) | 0.04 | 32 (BID) vs. 16 (QD) | <0.001 |
| Norwegian Lung Cancer Study Group (33) | Yes | 157 | 42 Gy/15 fractions QD | EP (4) | 53 (BID) vs. 42 (QD) | 25 (BID) vs. 19 (QD) | 0.61 | 31 (BID) vs. 33 (QD) | 0.80 |
| CONVERT (34) | Yes | 543 | 66 Gy/33 fractions QD | EP (4–6) | 56 (BID) vs. 51 (QD) | 30 (BID) vs. 25 (QD) | 0.15 | 19 (BID) vs. 19 (QD) | 0.85 |
| CALGB 30610/RTOG 0538 | No | 729 | 70 Gy/35 fractions QD | EP (4) | NA | NA | NA | NA | NA |
BID, twice daily treatments; QD, once daily treatments; EP, etoposide-cisplatin; OS, overall survival.